Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

Eliyahu Kalif Biography and Net Worth

CFO of Teva Pharmaceutical Industries

Eli Kalif was appointed Executive Vice President, Chief Financial Officer in December 2019, with primary responsibility for leading Teva's financial strategy and overseeing all the finance activities of the company, including treasury, financial planning and analysis, accounting, taxation matters and investor relations. Eli is also responsible for Teva's Information Technology (IT) globally and for setting up the Global Business Services function.

Teva’s Global Finance Group is a business partner to Teva's Global, Regional and BU leadership teams, ensuring that Teva has the right financial resources and tools to deliver on its objectives. Teva shares are listed on both the New York Stock Exchange and Tel Aviv Stock Exchange.

Eli is a senior finance executive with more than twenty years’ experience in corporate and operational finance, bringing proven leadership capabilities as well as deep functional expertise and technical knowledge in all aspects of corporate finance, financial planning and accounting. He possesses a profound understanding of global production structures and has experience in leading organizational transformations, as well as building world class financial organizations. Prior to joining Teva, Eli held various leadership and senior executive finance positions in Flex Ltd., a global technology design and manufacturing service provider. He was responsible for leading global finance teams.

Eli is a graduate of Stanford University and MIT Sloan executive programs and holds a BA degree in Accounting and Economics from the College of Management Academic Studies in Israel. He is also a certified Public Accountant (CPA).

What is Eliyahu Sharon Kalif's net worth?: The estimated net worth of Eliyahu Sharon Kalif is at least $1.29 million as of August 7th, 2023. Mr. Kalif owns 99,162 shares of Teva Pharmaceutical Industries stock worth more than $1,290,098 as of April 23rd. This net worth approximation does not reflect any other investments that Mr. Kalif may own. Additionally, Mr. Kalif receives an annual salary of $2,010,000.00 as CFO at Teva Pharmaceutical Industries. Learn More about Eliyahu Sharon Kalif's net worth.
How old is Eliyahu Sharon Kalif?: Mr. Kalif is currently 51 years old. There are 4 older executives and no younger executives at Teva Pharmaceutical Industries. Learn More on Eliyahu Sharon Kalif's age.
What is Eliyahu Sharon Kalif's salary?: As the CFO of Teva Pharmaceutical Industries Limited, Mr. Kalif earns $2,010,000.00 per year. Learn More on Eliyahu Sharon Kalif's salary.
How do I contact Eliyahu Sharon Kalif?: The corporate mailing address for Mr. Kalif and other Teva Pharmaceutical Industries executives is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. Teva Pharmaceutical Industries can also be reached via phone at (723) 914-8213 and via email at [email protected]. Learn More on Eliyahu Sharon Kalif's contact information.
Has Eliyahu Sharon Kalif been buying or selling shares of Teva Pharmaceutical Industries?: Eliyahu Sharon Kalif has not been actively trading shares of Teva Pharmaceutical Industries during the past quarter. Most recently, Eliyahu Sharon Kalif sold 35,125 shares of the business's stock in a transaction on Monday, August 7th. The shares were sold at an average price of $9.73, for a transaction totalling $341,766.25. Following the completion of the sale, the chief financial officer now directly owns 99,162 shares of the company's stock, valued at $964,846.26. Learn More on Eliyahu Sharon Kalif's trading history.
Who are Teva Pharmaceutical Industries' active insiders?: Teva Pharmaceutical Industries' insider roster includes Rosemary Crane (Director), Richard Daniell (VP), Sven Dethlefs (EVP), Eric Drape (VP), Hafrun Fridriksdottir (VP), Eric Hughes (insider), Eliyahu Kalif (CFO), Mark Sabag (Insider), Eli Shani (EVP), David Stark (VP), and Amir Weiss (CAO). Learn More on Teva Pharmaceutical Industries' active insiders.
Are insiders buying or selling shares of Teva Pharmaceutical Industries?: During the last twelve months, insiders at the sold shares 9 times. They sold a total of 480,586 shares worth more than $5,931,942.06. The most recent insider tranaction occured on March, 5th when EVP Mark Sabag sold 100,000 shares worth more than $1,352,000.00. Insiders at Teva Pharmaceutical Industries own 0.6% of the company. Learn More about insider trades at Teva Pharmaceutical Industries.
Information on this page was last updated on 3/5/2024.

Eliyahu Sharon Kalif Insider Trading History at Teva Pharmaceutical Industries

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/7/2023	Sell	35,125	$9.73	$341,766.25	99,162
8/22/2022	Sell	55,500	$10.07	$558,885.00	9,376

Eliyahu Sharon Kalif Buying and Selling Activity at Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Company Overview

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Today's Range

Now: $13.01

$12.78

$13.03

50 Day Range

MA: $13.50

$12.78

$14.44

2 Week Range

Now: $13.01

$7.09

$14.47

Volume

8,981,770 shs

Average Volume

10,621,822 shs

Market Capitalization

$14.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

From Paradigm Press | Ad

Click here to find out that this 8,788% cryptocurrency is.

Eliyahu Kalif Biography and Net Worth

What is Eliyahu Sharon Kalif's net worth?

How old is Eliyahu Sharon Kalif?

What is Eliyahu Sharon Kalif's salary?

How do I contact Eliyahu Sharon Kalif?

Has Eliyahu Sharon Kalif been buying or selling shares of Teva Pharmaceutical Industries?

Who are Teva Pharmaceutical Industries' active insiders?

Are insiders buying or selling shares of Teva Pharmaceutical Industries?